INFORMAZIONI SU QUESTO EPISODIO
In this episode of From Models to Medicine, we sit down with Mark Amouzgar, co-founder and CEO of March Health. Mark opens with a striking stat: general-purpose AI models are only about 60% accurate in women's health. Sounding confident isn't the same as being clinically safe, and in this episode he breaks down exactly why generic AI was never built for this.
We get into how March Health built a gender-aware digital twin, what it takes to wrap a model in real clinical logic, and why the average endometriosis patient sees eight different doctors before getting an accurate diagnosis. It's a candid conversation about a problem that doesn't get nearly enough attention.
-------------------------
Sign up for KAMI Think Tank's Maven course here!
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di From Models to Medicine.
ALTRI EPISODI IN QUESTO PODCAST
For this episode, we sit down with Banishree Saha, Global Biomarkers Lead at Takeda, who has worked in fields such as academic liver biology to translational biomarker work, over the course of her 20-year career. She walks us through what biomarkers really are, how flow cytometry went from single-c…
In this episode, we sit down with Chris Nelson, an mRNA scientist at nCode Bio whose career has taken him from building blood transfusion matching tests now used by the NHS, to cancer genomics at Personalis, to the frontier of mRNA sequence design. Chris breaks down why the untranslated regions of …
In this episode of From Models to Medicine, we sit down with Lavanya Anandan, Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering …
In this episode of From Models to Medicine, we sit down with Sarah Daniels, an environmental health researcher, who makes the argument that the chemicals making us sick might also be our best clues for building better drugs. She traces that idea from a 1976 discovery about dioxins all the way to an…
We chat with Karl Moritz, CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn't f…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da KAMI Think Tank, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
